Director David W. Gibbs filed a statement of changes in beneficial ownership with the SEC on November 9, 2026, disclosing the acquisition of 278 restricted stock units of Amgen Inc. common stock on November 6, 2026.

Key Highlights

  • Reporting person: David W. Gibbs, identified as a director of Amgen Inc. (NASDAQ:AMGN)
  • Transaction date: November 6, 2026
  • Securities acquired: 278 shares of common stock via RSU grant, acquired at a price of $0
  • Transaction code: A (acquisition), with the RSUs vesting immediately upon grant
  • Post-transaction ownership: 278 shares beneficially owned directly following the reported transaction
  • Grant program: RSUs issued under the Amgen Inc. 2009 Director Equity Incentive Program, as amended
  • Deferral option: Vested RSUs may be deferred by the director, with payment occurring according to an elected deferral schedule

RSU Grant Details for Amgen Director Gibbs in November 2026

According to the filing, David W. Gibbs, a director of Amgen Inc. (NASDAQ:AMGN), received 278 restricted stock units on November 6, 2026, at a price of $0 per unit. The grant was made pursuant to the Amgen Inc. 2009 Director Equity Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan. The filing reports that the RSUs vested immediately upon grant.

The filing states that vested RSUs are paid in shares of Amgen's common stock on a one-to-one basis, meaning each RSU corresponds to one share of common stock. Amgen is a global biopharmaceutical company whose equity incentive programs for directors are governed by the plans cited above. The filing also discloses that vested RSUs may be deferred by the director, in which case payment occurs according to the elected deferral schedule. Following the transaction, Gibbs beneficially owned 278 shares directly, as reported in Table I of the filing. The filing was signed by Andrea A. Robinson as Attorney-In-Fact for Mr. Gibbs and was filed on November 9, 2026.

What Was Disclosed

The filing disclosed that Amgen director David W. Gibbs acquired 278 immediately vesting RSUs on November 6, 2026, at no cost, under Amgen's director equity incentive program, resulting in direct beneficial ownership of 278 shares of common stock.